{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-057035","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.427896+00:00","generated_at":"2026-06-02T06:10:51.600541+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"4DMT Q1 2024 net loss $32.4M; advances 4D-150 toward Phase 3 for wet AMD","bullets":["Net loss $32.4M in Q1 2024 vs $28.7M in Q1 2023.","Cash $589M after $337M gross proceeds from upsized follow-on; runway into H1 2027.","4D-150 wet AMD: 89% injection burden reduction, 84% patients with 0-1 injections at 24 wks; Phase 3 start Q1 2025.","Upcoming: 4D-150 broader wet AMD data at ASRS July 2024; 4D-710 CF interim data at ECFS June 2024.","R&D expenses $27.9M, G&A $10.3M; both up YoY driven by clinical trial progression and headcount."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-057035","json":"https://secwatch.observer/filing/0000950170-24-057035.json","markdown":"https://secwatch.observer/filing/0000950170-24-057035.md","text":"https://secwatch.observer/filing/0000950170-24-057035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024057035/0000950170-24-057035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024057035/fdmt-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:10:51.600541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f45723328b6d92befb2af790b23adacffbaba7a1","claim":"4D Molecular Therapeutics, Inc. reported financial results for the three months ended March 31, 2024.","evidence_excerpt":"4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024057035/0000950170-24-057035-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}